GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
11 juin 2024 09h00 HE
|
GRI Bio, Inc.
Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
22 mai 2024 09h15 HE
|
GRI Bio, Inc.
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to...
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
21 mai 2024 08h35 HE
|
GRI Bio, Inc.
Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025...
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
20 mai 2024 08h45 HE
|
GRI Bio, Inc.
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score...
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
14 mai 2024 09h05 HE
|
GRI Bio, Inc.
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
13 mai 2024 16h45 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024.Received $0.5...
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
13 mai 2024 08h00 HE
|
GRI Bio, Inc.
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 ...
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
29 avr. 2024 08h45 HE
|
GRI Bio, Inc.
LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
25 avr. 2024 09h15 HE
|
GRI Bio, Inc.
Live webcast on Wednesday, May 1st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
08 avr. 2024 08h35 HE
|
GRI Bio, Inc.
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...